Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06102005 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 685
- Enrollment target
NCT06102005: Completed Phase 2 study, sponsored by Sanofi.
NCT06102005 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 685 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (415% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06102005, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 685 participants
- Enrollment target
Study Summary
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Interventions
- DRUG Placebo
- DRUG Lunsekimig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2026-03-11 |
| Phase | Phase 2 |
What the finished NCT06102005 record still lists
NCT06102005 is an interventional study that assigns participants to a tested intervention. The registered 685 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (415% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06102005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06102005 about?
NCT06102005 is a clinical study titled "Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma". This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
What is the current status of trial NCT06102005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 685 participants. The study started on 2023-10-16. Estimated completion is 2026-03-11.
What interventions are being tested in trial NCT06102005?
The interventions under investigation include: Placebo (DRUG), Lunsekimig (DRUG).
Who is sponsoring clinical trial NCT06102005?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06102005's enrollment target sits among peer trials
685 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI